Certara (NASDAQ:CERT – Free Report) had its target price increased by Barclays from $7.50 to $9.00 in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has an equal weight rating on the stock.
Other research analysts have also issued research reports about the stock. Weiss Ratings upgraded shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday, August 5th. UBS Group reiterated a “neutral” rating and issued a $10.00 target price on shares of Certara in a research report on Wednesday, September 30th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Certara currently has an average rating of “Hold” and a consensus target price of $8.60.
Get Our Latest Stock Analysis on Certara
Certara Trading Up 5.7%
Certara (NASDAQ:CERT – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $93.27 million during the quarter, compared to analyst estimates of $98.09 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. Certara’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.07 EPS. As a group, analysts predict that Certara will post 0.22 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Certara
Institutional investors have recently made changes to their positions in the company. Central Pacific Bank Trust Division increased its stake in shares of Certara by 8.7% during the 2nd quarter. Central Pacific Bank Trust Division now owns 19,460 shares of the company’s stock worth $127,000 after purchasing an additional 1,558 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Certara by 21.2% in the 3rd quarter. GAMMA Investing LLC now owns 9,778 shares of the company’s stock valued at $90,000 after purchasing an additional 1,710 shares during the last quarter. Sequoia Financial Advisors LLC lifted its stake in shares of Certara by 12.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 17,906 shares of the company’s stock valued at $117,000 after purchasing an additional 1,923 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Certara by 12.1% in the 1st quarter. The Manufacturers Life Insurance Company now owns 23,289 shares of the company’s stock valued at $133,000 after purchasing an additional 2,513 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its holdings in Certara by 28.1% in the first quarter. Pacer Advisors Inc. now owns 13,093 shares of the company’s stock worth $75,000 after purchasing an additional 2,871 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.
About Certara
Certara, Inc (NASDAQ:CERT) provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle.
Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis.
Further Reading
- Five stocks we like better than Certara
- Alphabet Introduces Gemini Agent—Can It Trigger a Breakout?
- Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November Earnings
- Tilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform
- Arista Networks Plugs Into All-Time Highs
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.
